Torthaí cuardaigh - Debashis Sarker

Beachtaigh na torthaí
  1. 1
    Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics

    Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics de réir Debra H. Josephs, Debashis Sarker

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

    Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer de réir Debashis Sarker, Alison Reid, Timothy A. Yap, Johann S. de Bono

    Foilsithe / Cruthaithe 2009
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

    Improving the outcome of patients with castration-resistant prostate cancer through rational drug development de réir Gerhardt Attard, Debashis Sarker, Alison Reid, R. Molife, Chris Parker, Johann S. de Bono

    Foilsithe / Cruthaithe 2006
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Effect of Patient Socioeconomic Status on Access to Early-Phase Cancer Trials

    Effect of Patient Socioeconomic Status on Access to Early-Phase Cancer Trials de réir Aisyah Mohd Noor, Debashis Sarker, Suzanne Vizor, Blair Kp McLennan, Sarah Hunter, Aneta Suder, Henrik Møller, James Spicer, Sophie Papa

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study

    Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study de réir Sam Sollie, Dominique S. Michaud, Debashis Sarker, Sophia N. Karagiannis, Debra H. Josephs, Niklas Hammar, Aida Santaolalla, Göran Walldius, Hans Garmo, Lars Holmberg, Ingmar Jungner, Mieke Van Hemelrijck

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

    First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer de réir Christophe Massard, A. Ázaro, Jean‐Charles Soria, Ulrik Lassen, Christophe Le Tourneau, Debashis Sarker, Claire Smith, U. Ohnmacht, Gerard J. Oakley, Bharvin K.R. Patel, Eunice Yuen, Karim A. Benhadji, Jordi Rodón

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor

    First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor de réir Ruth Plummer, Divyanshu Dua, Nicola Cresti, Yvette Drew, Peter Stephens, Marie L. Foegh, Steen Knudsen, Perminder S. Sachdev, Bipin Mistry, Vaishali Dixit, Sharon McGonigle, Nancy Hall, Mark Matijevic, Shannon McGrath, Debashis Sarker

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer

    A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer de réir Rebecca Kristeleit, Ruth Plummer, Robert H. Jones, Louise Carter, Sarah P. Blagden, Debashis Sarker, Hendrik‐Tobias Arkenau, T.R. Jeffry Evans, Sarah Danson, Stefan N. Symeonides, Gareth J. Veal, Barbara Klencke, Mark Kowalski, Udai Banerji

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours

    Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours de réir Nicholas C. Turner, Sandra J. Strauss, Debashis Sarker, Roopinder Gillmore, Amy A. Kirkwood, A. Hackshaw, Anthie Papadopoulou, J. Bell, Irfan Kayani, Christos Toumpanakis, Federica Grillo, A Mayer, Daniel Hochhauser, Richard H. J. Beǵent, Martyn Caplin, Tim Meyer

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

    A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors de réir Debashis Sarker, R. Molife, T. R. J. Evans, Maryon Hardie, Cheryl Marriott, Priska Butzberger-Zimmerli, Rosemary Morrison, Judith A. Fox, Carla Heise, Sharianne G. Louie, Natasha Aziz, F. Garzon, Glenn Michelson, Ian Judson, Dalal Jadayel, Edgar Braendle, Johann S. de Bono

    Foilsithe / Cruthaithe 2008
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer

    USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer de réir Jessica K. Nelson, May Zaw Thin, Theodore Evan, Steven Howell, Mary Wu, Bruna Almeida, Nathalie Legrave, Duco S. Koenis, Gabriela Koifman, Yoichiro Sugimoto, Miriam Llorián Sopeña, James I. MacRae, Emma Nye, Michael Howell, Ambrosius P. Snijders, Andreas Prachalias, Yoh Zen, Debashis Sarker, Axel Behrens

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Quantification of Pancreatic Cancer Proteome and Phosphorylome: Indicates Molecular Events Likely Contributing to Cancer and Activity of Drug Targets

    Quantification of Pancreatic Cancer Proteome and Phosphorylome: Indicates Molecular Events Likely Contributing to Cancer and Activity of Drug Targets de réir D. Britton, Yoh Zen, Alberto Quaglia, Stefan Selzer, Vikram Mitra, Christopher Lößner, Stephan Jung, Gitte Böhm, Peter Schmid, Petra Prefot, Claudia Hoehle, Saša Končarević, Julia M.W. Gee, Robert I. Nicholson, Malcolm Ward, Leandro Castellano, Justin Stebbing, Hans Dieter Zucht, Debashis Sarker, Nigel Heaton, Ian Pike

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

    1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC) de réir Mimi I. Hu, Vivek Subbiah, Lori J. Wirth, M Schuler, Aaron S. Mansfield, Marcia S. Brose, Giuseppe Curigliano, Sophie Leboulleux, Viola W. Zhu, Bhumsuk Keam, Ignacio Matos, C-C. Lin, D.R. Adkins, Christina S. Baik, G. Lopes, Yann Godbert, Debashis Sarker, H. Zhang, Christopher D. Turner, Matthew Taylor

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 14
    The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

    The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanc... de réir Udai Banerji, D. Ross Camidge, Henk M.W. Verheul, Roshan Agarwal, Debashis Sarker, Stan B. Kaye, Ingrid M.E. Desar, Johanna N.H. Timmer-Bonte, Sabine Eckhardt, Karl D. Lewis, Kathryn H. Brown, Mireille Cantarini, Clive Morris, Sarah M.A. George, Paul D. Smith, Carla M.L. van Herpen

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 15
    Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

    Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib de réir Masatoshi Kudo, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Thomas Yau, Ellen B. Gurary, Abby B. Siegel, Anran Wang, Ann‐Lii Cheng, Andrew X. Zhu

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 16
    Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2

    Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2 de réir Hemant M. Kocher, Charlotte Ackerman, Garima Priyadarshini, Cheryl Lawrence, Nishtha Kotriwala, Ramona Georgescu, Rhiannon Roberts, Christine S. Hughes, Ahmet Imrali, Claude Chelala, Judith Dixon-Hughes, David K. Chang, Peter Sasieni, Pippa Corrie, Mairéad G. McNamara, Debashis Sarker, Fieke E. M. Froeling, Alan Christie, Roopinder Gillmore, Khurum Khan, David Propper

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 17
    Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer

    Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer de réir Hemant M. Kocher, Bristi Basu, Fieke E. M. Froeling, Debashis Sarker, Sarah Slater, Dominic Carlin, Nandita M. deSouza, Katja N. De Paepe, Michelle R. Goulart, Christine S. Hughes, Ahmet Imrali, Rhiannon Roberts, Maria Pawula, Richard Houghton, Cheryl Lawrence, Yathushan Yogeswaran, Kelly Mousa, Carike Coetzee, Peter Sasieni, Aaron Prendergast, David Propper

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  18. 18
    First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

    First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors de réir Debashis Sarker, Joo Ern Ang, Richard D. Baird, Rebecca Kristeleit, Krunal Shah, Víctor Moreno, Paul A. Clarke, Florence I. Raynaud, Gallia G. Levy, Joseph A. Ware, Kathryn Mazina, Ray Lin, Jenny Wu, Jill Fredrickson, Jill M. Spoerke, Mark R. Lackner, Yibing Yan, Lori S. Friedman, Stan B. Kaye, Mika K. Derynck, Paul Workman, Johann S. de Bono

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  19. 19
    Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

    Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial de réir Gontran Verset, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Vittorina Zagonel, Per Stål, Debashis Sarker, Daniel H. Palmer, Arndt Vogel, Julien Edeline, Stéphane Cattan, Masatoshi Kudo, Ann‐Lii Cheng, Sadahisa Ogasawara, Bruno Daniele, Stephen L. Chan, Jennifer J. Knox, Shukui Qin, Abby B. Siegel, Michael Chisamore, Ken Hatogai, Anran Wang, Richard S. Finn, Andrew X. Zhu

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  20. 20
    CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells

    CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells de réir Rémi Samain, Óscar Maiques, Joanne Monger, Hoyin Lam, Juliana Candido, Samantha L. George, Nicola Ferrari, Leonie KohIhammer, Sophia Lunetto, A. Senra Varela, José L. Orgaz, F Vilardell, Jorge Juan Olsina Kissler, Xavier Matías‐Guiu, Debashis Sarker, Adrian Biddle, Frances R. Balkwill, Jim Eyles, Robert W. Wilkinson, Hemant M. Kocher, Fernando Calvo, Claire M. Wells, Victoria Sanz‐Moreno

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: